Skip to content

A clinical retrospective cohort study of PBC complicated with infection

A clinical retrospective cohort study of PBC complicated with infection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118768
Enrollment
Unknown
Registered
2026-02-10
Start date
2026-02-20
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary biliary cholangitis

Interventions

Control group:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients meeting the inclusion criteria all conform to the diagnostic criteria of the Practice Guidance for PBC issued by the American Association for the Study of Liver Diseases in 2018: 1) Laboratory tests of serum biochemistry show elevated alkaline phosphatase; 2). Positive anti - mitochondrial antibody or, when AMA is negative, positive for other specific antibodies of PBC (gp210, sp100); 3). Liver histological evidence suggests the presence of non - suppurative destructive cholangitis and interlobular bile duct damage; Diagnosis of PBC can be made if two of the above three criteria are met. 2. Follow-up duration >= 6 months; 3. Clinical data completeness > 70%

Exclusion criteria

Exclusion criteria: 1. Combine with other liver diseases, such as alcoholic liver disease, viral hepatitis, drug-induced liver injury, and other autoimmune liver diseases, etc. 2.Unable to judge the clinical efficacy, those who did not take the medicine as prescribed, and those with incomplete medical records; 3. Pregnant women, lactating women, or those with a plan to have children during the study period; 4. Those who have taken hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole, rifampicin, etc.) for more than 2 weeks within 6 months before screening, and those who have taken hormones for a long time; 5. Those with a history of severe heart, cerebrovascular, kidney, respiratory system diseases or organ failure, as well as mental diseases (including mental diseases caused by alcohol and drug abuse); 6. Other situations that the researcher deems unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Whether there is PBC progression;

Secondary

MeasureTime frame
Progression Free Survival, PFS;

Countries

China

Contacts

Public ContactJun Wu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

junwu77@hust.edu.cn+86 27 8572 6375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026